Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
iShares Neuroscience and Healthcare ETF ETF · iShares Trust
84 holdings · as of 2026-04-30 (4.6 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 109% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 12.85% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 51% turns out to be. Matching more holdings can only raise this share, never lower it.
84 holdings, 47 matched (53% of weight). Portfolio as of 2026-04-30, filed 2026-06-25. Source: SEC Form N-PORT.
5.86% of this portfolio’s income is non-permissible — weighted across holdings, computed over 34% of portfolio weight (32 of 84 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | UNSCREENED | 8.57% | no in-house ratios for this holding |
| Xenon Pharmaceuticals Inc | UNSCREENED | 4.79% | no in-house ratios for this holding |
| AXSM AXSOME THERAPEUTICS, INC. | COMPLIANT | 4.59% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | COMPLIANT | 4.41% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALKS ALKERMES PUBLIC LIMITED COMPANY | COMPLIANT | 4.20% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CENTESSA PHARMACEUTICALS PLC | UNSCREENED | 3.95% | no in-house ratios for this holding |
| ARGX argenx SE | COMPLIANT | 3.88% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| PTCT PTC THERAPEUTICS, INC. | NON_COMPLIANT | 3.69% | AAOIFI11.9% Usmani21.4% Dow Jones Islamic16.9% S&P Shariah20.0% MSCI Islamic21.2% MSCI Islamic M-Series20.0% FTSE Shariah18.2% |
| NBIX NEUROCRINE BIOSCIENCES, INC. | COMPLIANT | 3.68% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| BIIB BIOGEN INC. | COMPLIANT | 3.67% | AAOIFI21.2% Usmani22.5% Dow Jones Islamic27.5% S&P Shariah24.3% MSCI Islamic22.5% MSCI Islamic M-Series24.3% FTSE Shariah21.3% |
| Scholar Rock Holding Corp | UNSCREENED | 3.67% | no in-house ratios for this holding |
| Praxis Precision Medicines Inc | UNSCREENED | 3.66% | no in-house ratios for this holding |
| ACAD ACADIA PHARMACEUTICALS INC. | COMPLIANT | 3.61% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| Dianthus Therapeutics Inc | UNSCREENED | 3.39% | no in-house ratios for this holding |
| CATALYST PHARMACEUTICALS, INC. | UNSCREENED | 3.29% | no in-house ratios for this holding |
| Denali Therapeutics Inc | UNSCREENED | 2.82% | no in-house ratios for this holding |
| SUPN SUPERNUS PHARMACEUTICALS, INC. | COMPLIANT | 2.78% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| Edgewise Therapeutics Inc | UNSCREENED | 2.53% | no in-house ratios for this holding |
| Dyne Therapeutics, Inc | UNSCREENED | 2.36% | no in-house ratios for this holding |
| AXGN AxoGen, Inc. | COMPLIANT | 2.34% | AAOIFI0.8% Usmani6.6% Dow Jones Islamic1.7% S&P Shariah2.2% MSCI Islamic6.6% MSCI Islamic M-Series2.2% FTSE Shariah0.0% |
| SAREPTA THERAPEUTICS, INC. | UNSCREENED | 2.21% | no in-house ratios for this holding |
| 326030.KS SK Biopharmaceuticals Co Ltd | COMPLIANT | 2.04% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| HLUN-A.CO H. LUNDBECK A/S | COMPLIANT | 1.92% | AAOIFIpass Usmanipass Dow Jones Islamicfail S&P Shariahfail MSCI Islamicpass MSCI Islamic M-Seriesfail FTSE Shariahpass |
| Capricor Therapeutics Inc | UNSCREENED | 1.75% | no in-house ratios for this holding |
| TSHA Taysha Gene Therapies Inc | NON_COMPLIANT | 1.53% | AAOIFI3.1% Usmani12.1% Dow Jones Islamic5.9% S&P Shariah7.4% MSCI Islamic12.0% MSCI Islamic M-Series7.4% FTSE Shariah10.5% |
| BIOA-B.ST BioArctic AB | COMPLIANT | 1.37% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| Biohaven Ltd | UNSCREENED | 1.30% | no in-house ratios for this holding |
| NEU.AX Neuren Pharmaceuticals Ltd | NON_COMPLIANT | 1.06% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Rapport Therapeutics Inc | UNSCREENED | 1.03% | no in-house ratios for this holding |
| DYVOX.ST Dynavox Group AB | COMPLIANT | 0.94% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| Bright Minds Biosciences Inc | UNSCREENED | 0.92% | no in-house ratios for this holding |
| IDIA.SW Idorsia Ltd | NON_COMPLIANT | 0.87% | AAOIFI97.6% Usmani296.1% Dow Jones Islamic— S&P Shariah— MSCI Islamic272.0% MSCI Islamic M-Series— FTSE Shariah272.0% |
| ANNX Annexon Inc | COMPLIANT | 0.80% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Alto Neuroscience Inc | UNSCREENED | 0.78% | no in-house ratios for this holding |
| SanBio Company Limited | UNSCREENED | 0.75% | no in-house ratios for this holding |
| IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION | NON_COMPLIANT | 0.75% | AAOIFI68.0% Usmani24.8% Dow Jones Islamic70.3% S&P Shariah50.6% MSCI Islamic24.8% MSCI Islamic M-Series50.6% FTSE Shariah19.8% |
| MEDCL.PA Medincell SA | COMPLIANT | 0.65% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| LB Pharmaceuticals Inc | UNSCREENED | 0.63% | no in-house ratios for this holding |
| BRSYF Brainsway Ltd | COMPLIANT | 0.60% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| CBLL Ceribell Inc | COMPLIANT | 0.52% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| PRTA Prothena Corporation PLC | NON_COMPLIANT | 0.51% | AAOIFI1.4% Usmani2.3% Dow Jones Islamic1.2% S&P Shariah0.8% MSCI Islamic2.3% MSCI Islamic M-Series0.8% FTSE Shariah0.0% |
| Zylox-Tonbridge Medical Technology Co Ltd | UNSCREENED | 0.51% | no in-house ratios for this holding |
| 4588.T Oncolys Biopharma Inc | NON_COMPLIANT | 0.49% | AAOIFI0.3% Usmani7.5% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic7.0% MSCI Islamic M-Seriesfail FTSE Shariah7.0% |
| RLMD Relmada Therapeutics Inc | NON_COMPLIANT | 0.48% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Solid Biosciences Inc | UNSCREENED | 0.46% | no in-house ratios for this holding |
| MicroPort NeuroScientific Corp | UNSCREENED | 0.46% | no in-house ratios for this holding |
| Design Therapeutics Inc | UNSCREENED | 0.46% | no in-house ratios for this holding |
| NPCE Neuropace Inc | COMPLIANT | 0.46% | AAOIFI13.7% Usmani72.1% Dow Jones Islamic17.1% S&P Shariah19.3% MSCI Islamic72.1% MSCI Islamic M-Series19.3% FTSE Shariah60.8% |
| RGNX Regenxbio Inc | NON_COMPLIANT | 0.44% | AAOIFI11.7% Usmani17.8% Dow Jones Islamic14.0% S&P Shariah12.0% MSCI Islamic17.8% MSCI Islamic M-Series12.0% FTSE Shariah0.0% |
| BNTC Benitec Biopharma Inc | NON_COMPLIANT | 0.42% | AAOIFI0.2% Usmani0.4% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.4% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| MPLT MapLight Therapeutics Inc | NON_COMPLIANT | 0.42% | AAOIFI0.3% Usmani0.5% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.5% MSCI Islamic M-Series— FTSE Shariah0.0% |
| VNDA VANDA PHARMACEUTICALS INC. | COMPLIANT | 0.41% | AAOIFI5.1% Usmani5.5% Dow Jones Islamic4.9% S&P Shariah5.2% MSCI Islamic3.8% MSCI Islamic M-Series5.2% FTSE Shariah0.0% |
| 9996.HK PEIJIA MEDICAL LIMITED | COMPLIANT | 0.40% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| NWRN.SW Newron Pharmaceuticals SpA | COMPLIANT | 0.35% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| NGNE NEUROGENE INC. | NON_COMPLIANT | 0.34% | AAOIFI1.1% Usmani3.4% Dow Jones Islamic2.2% S&P Shariah2.5% MSCI Islamic3.4% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| OVID OVID THERAPEUTICS INC. | NON_COMPLIANT | 0.34% | AAOIFI2.3% Usmani5.5% Dow Jones Islamic8.0% S&P Shariah7.3% MSCI Islamic5.5% MSCI Islamic M-Series7.3% FTSE Shariah0.0% |
| Anavex Life Sciences Corp | UNSCREENED | 0.32% | no in-house ratios for this holding |
| TRDA Entrada Therapeutics Inc | NON_COMPLIANT | 0.31% | AAOIFI17.5% Usmani16.2% Dow Jones Islamic12.3% S&P Shariah11.3% MSCI Islamic16.2% MSCI Islamic M-Series11.3% FTSE Shariah0.0% |
| CLPT Clearpoint Neuro Inc | COMPLIANT | 0.31% | AAOIFI15.0% Usmani73.7% Dow Jones Islamic16.2% S&P Shariah20.0% MSCI Islamic73.7% MSCI Islamic M-Series20.0% FTSE Shariah57.9% |
| SANN.SW Santhera Pharmaceuticals Holding AG | COMPLIANT | 0.28% | AAOIFI21.0% Usmani34.4% Dow Jones Islamicpass S&P Shariahpass MSCI Islamic33.1% MSCI Islamic M-Seriespass FTSE Shariah33.1% |
| ACIU AC Immune SA | NON_COMPLIANT | 0.20% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| ALEC Alector Inc | NON_COMPLIANT | 0.19% | AAOIFI11.9% Usmani16.1% Dow Jones Islamic14.3% S&P Shariah10.0% MSCI Islamic16.1% MSCI Islamic M-Series10.0% FTSE Shariah4.9% |
| IKT Inhibikase Therapeutics Inc | NON_COMPLIANT | 0.19% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| VYGR Voyager Therapeutics Inc | NON_COMPLIANT | 0.18% | AAOIFI17.2% Usmani16.5% Dow Jones Islamic13.5% S&P Shariah11.1% MSCI Islamic16.5% MSCI Islamic M-Series11.1% FTSE Shariah0.0% |
| Larimar Therapeutics Inc | UNSCREENED | 0.18% | no in-house ratios for this holding |
| TONIX PHARMACEUTICALS HOLDING CORP. | UNSCREENED | 0.17% | no in-house ratios for this holding |
| Myung In Pharm Co Ltd | UNSCREENED | 0.16% | no in-house ratios for this holding |
| Neumora Therapeutics Inc | UNSCREENED | 0.15% | no in-house ratios for this holding |
| ABOS Acumen Pharmaceuticals Inc | NON_COMPLIANT | 0.12% | AAOIFI15.5% Usmani27.2% Dow Jones Islamic25.0% S&P Shariah20.8% MSCI Islamic27.2% MSCI Islamic M-Series20.8% FTSE Shariah27.2% |
| PEPG PepGen Inc | NON_COMPLIANT | 0.11% | AAOIFI7.5% Usmani11.4% Dow Jones Islamic9.4% S&P Shariah7.4% MSCI Islamic11.4% MSCI Islamic M-Series7.4% FTSE Shariah0.0% |
| CGTX Cognition Therapeutics Inc | NON_COMPLIANT | 0.11% | AAOIFI0.5% Usmani1.3% Dow Jones Islamic0.7% S&P Shariah0.8% MSCI Islamic1.3% MSCI Islamic M-Series0.8% FTSE Shariah0.0% |
| BrainAurora Medical Technology Ltd | UNSCREENED | 0.09% | no in-house ratios for this holding |
| GANX Gain Therapeutics Inc | COMPLIANT | 0.07% | AAOIFI0.8% Usmani4.0% Dow Jones Islamic0.9% S&P Shariah1.0% MSCI Islamic4.0% MSCI Islamic M-Series1.0% FTSE Shariah2.2% |
| FLNA Filana Therapeutics, Inc | NON_COMPLIANT | 0.07% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| SGMOQ SANGAMO THERAPEUTICS, INC. | NON_COMPLIANT | 0.05% | AAOIFI29.9% Usmani35.1% Dow Jones Islamic12.4% S&P Shariah13.9% MSCI Islamic35.1% MSCI Islamic M-Series13.9% FTSE Shariah0.0% |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency Shares | UNSCREENED | 0.05% | no in-house ratios for this holding |
| AUSTRALIAN DOLLAR | UNSCREENED | 0.02% | no in-house ratios for this holding |
| JAPANESE YEN | UNSCREENED | 0.02% | no in-house ratios for this holding |
| SWISS FRANC | UNSCREENED | 0.01% | no in-house ratios for this holding |
| SWEDISH KRONE | UNSCREENED | 0.00% | no in-house ratios for this holding |
| KOREAN WON | UNSCREENED | 0.00% | no in-house ratios for this holding |
| HONG KONG DOLLAR | UNSCREENED | 0.00% | no in-house ratios for this holding |
| EURO | UNSCREENED | 0.00% | no in-house ratios for this holding |
| DANISH KRONER | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 11 points of portfolio weight — 28.1% of it passes AAOIFI, 17.5% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 28.1% ratios fail on 12.9% 67.6% not rated under AAOIFI
ratios pass on 19.3% ratios fail on 19.2% 70.2% not rated under Usmani
ratios pass on 26.0% ratios fail on 13.0% 69.6% not rated under Dow Jones Islamic
ratios pass on 26.2% ratios fail on 12.1% 70.3% not rated under S&P Shariah
ratios pass on 17.5% ratios fail on 20.9% 70.2% not rated under MSCI Islamic
ratios pass on 26.0% ratios fail on 12.5% 70.1% not rated under MSCI Islamic M-Series
ratios pass on 19.5% ratios fail on 18.9% 70.2% not rated under FTSE Shariah
47 of 84 listed holdings carry our own per-methodology verdicts (57% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 31 (28% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| PTCT PTC THERAPEUTICS, INC. | 3.69% |
| TSHA Taysha Gene Therapies Inc | 1.53% |
| NEU.AX Neuren Pharmaceuticals Ltd | 1.06% |
| IDIA.SW Idorsia Ltd | 0.87% |
| IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION | 0.75% |
| PRTA Prothena Corporation PLC | 0.51% |
| 4588.T Oncolys Biopharma Inc | 0.49% |
| RLMD Relmada Therapeutics Inc | 0.48% |
| RGNX Regenxbio Inc | 0.44% |
| BNTC Benitec Biopharma Inc | 0.42% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
IBRN (IBRN) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for IBRN — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 34.00 | NEUTRAL |
| Stochastic %K (14) | 7.18 | BUY |
| CCI (20) | -113.79 | BUY |
| Williams %R (14) | -92.82 | BUY |
| MACD (12,26,9) | -0.34 | SELL |
| ROC (10) | -7.81 | SELL |
| Momentum (10) | -3.07 | SELL |
| EMA (10) | 37.17 | SELL |
| SMA (10) | 37.27 | SELL |
| EMA (20) | 37.85 | SELL |
| SMA (20) | 38.43 | SELL |
| EMA (30) | 38.07 | SELL |
| SMA (30) | 38.77 | SELL |
| EMA (50) | 37.99 | SELL |
| SMA (50) | 38.34 | SELL |
| EMA (100) | 36.99 | SELL |
| SMA (100) | 37.10 | SELL |
| EMA (200) | 34.68 | BUY |
| SMA (200) | 34.77 | BUY |
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 44 |
| ⏱ 15-Min | BEARISH | 29 |
| ⏲ 5-Min | BEARISH | 88 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.